A Study to Evaluate the Safety of Rapid and Conventional Rituximab Infusion in a Tertiary Care Centre

Janardhanan, M and Nayak, V and Thomas, J and Bairy, KL (2016) A Study to Evaluate the Safety of Rapid and Conventional Rituximab Infusion in a Tertiary Care Centre. International Journal of Toxicological and Pharmacological Research, 8 (4). pp. 237-242. ISSN 0975-5160

[img] PDF
1041DisplayPdf.pdf - Published Version
Restricted to Registered users only

Download (418kB) | Request a copy


Antibody-based therapy, in particular rituximab, is a promising strategy in the treatment of Non-Hodgkin lymphoma. Rituximab chemotherapy combinations have revolutionised the treatment outcomes in NHL. A major barrier to effective treatment of rituximab is the lengthy infusion time. Hence, by reducing the chair time of one patient from the conventional 4-6 hours to rapid (90 minutes) infusion, more number of patients can be accommodated in outpatient facility. A total of 40 patients who received rapid infusion of rituximab over 90 minutes and 30 patients who received conventional infusion were evaluated for the safety parameter. It was observed that rapid infusion was well tolerated with no grade 3 or 4 reaction and there was no significant difference in the safety analysis between the rapid and conventional infusion. Therefore, it can be concluded that rapid infusion of rituximab can be opted as a safer alternative to conventional infusion and also improves patient satisfaction

Item Type: Article
Uncontrolled Keywords: Non-Hodgkin lymphoma; Infusion-related; Diffuse large B-cell; Adverse events
Subjects: Medicine > KMC Mangalore > Pharmacology
Medicine > KMC Mangalore > Radiotherapy and Oncology
Depositing User: KMC Library
Date Deposited: 02 Sep 2016 14:48
Last Modified: 02 Sep 2016 14:48
URI: http://eprints.manipal.edu/id/eprint/146904

Actions (login required)

View Item View Item